Real-World Observations in Obstructive Hypertrophic Cardiomyopathy Patients Treated with Mavacamten: Evidence of Favorable Disease Modification.

Background: Mavacamten is commercially approved for use in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients. This study evaluated its real-world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy (SRT) in oHCM patients treated at a multi-hospital referral center.

Methods: We included 244 oHCM patients (mean age 64 years, 57% female, 21% with atrial fibrillation, 51% New York Heart Association [NYHA] Class III, 82% on beta-blockers) treated with mavacamten for ≥3 months (171 for ≥12 months).

Chronic Kidney Disease as a Predictor of Mortality in Hospitalized Inflammatory Bowel Disease Patients With Clostridioides difficile Infection.

Introduction Clostridioides difficile infection (CDI) leads to significant morbidity and mortality in hospitalized patients. We aim to investigate whether chronic kidney disease (CKD) or end-stage renal disease (ESRD) are predictors of mortality in admitted patients with CDI, and whether the presence of inflammatory bowel disease (IBD) has any impact on the mortality rate.  Methods The data of 133,099 hospitalized patients with CDI were analyzed from the National Inpatient Sample (NIS) database from 2016 to 2018.

Calcium and vitamin D supplementation impact on survival in patients with moderate concomitant aortic and mitral valve disease.

Calcium supplement intake, with or without vitamin D supplementation, has risen amongst the older population, who are more likely to have deficiencies. Our aim was to investigate how the supplementation of calcium and vitamin D is associated with survival in patients with moderate concomitant aortic and mitral valve disease. A total of 3,257 patients (mean age of 71.

Real-World Artificial Intelligence-Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy.

Background: There is an emerging interest in artificial intelligence-enhanced 12-lead electrocardiogram (AI-ECG) in detection of hypertrophic cardiomyopathy (HCM).

Objectives: This study describes the initial real-world experience of using AI-ECG (Viz-HCM, developed using a convolutional neural network trained algorithm) in our center.

Methods: All patients undergoing 12-lead electrocardiograms at Cleveland Clinic, Cleveland, Ohio, between February 19, 2024, and November 1, 2024, were prospectively analyzed for potential HCM using AI-ECG.

Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy.

Background: In hypertrophic cardiomyopathy, histologic findings like myocyte hypertrophy and disarray, interstitial fibrosis (IF), and small intramural coronary artery dysplasia (SICAD) result in left ventricular hypertrophy, diastolic dysfunction, arrhythmogenicity, and microvascular ischemia.

Objectives: The authors sought to evaluate the association between histology and outcomes in obstructive hypertrophic cardiomyopathy (oHCM) patients undergoing surgical myectomy (SM).

Methods: The study included 1,722 symptomatic oHCM patients (mean age: 56 ± 14 years; 948 [55%] men) who underwent SM at a tertiary center between 2005 and 2018.

Long-Term Outcomes of Patients With Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score.

Background: Apical hypertrophic cardiomyopathy (aHCM) is a distinct variant characterized by predominant hypertrophy of the left ventricle apex.

Objectives: This study sought to describe aHCM patients' characteristics and develop a risk score for aHCM patients.

Methods: A total of 462 patients (age 58 ± 15 years, 68% male) diagnosed with aHCM were included.

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.

Background: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain.

Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.

Introduction: Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic heart disease with an estimated prevalence in the general population of 0.2% to 0.6%.